

Redx Pharma addresses flagship antibiotic conference

30 Nov 2013

Redx Pharma's CEO Dr Neil Murray joined a panel of business leaders, academics and public health experts at an international conference to debate the response to the global threat of antibiotic resistance.

The one-day event, BioInfect 2013, took place at AstraZeneca's Alderley Park facility in the UK and was organised by Bionow, BioHub and Redx Pharma. It examined the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.

The conference contributed to setting a new national and international agenda regarding the development of legislation, regulation, research focus and international trends in the critical area of meeting the growing challenge of anti-microbial resistance.

The event featured responses keynote addresses from the UK CMO Dame Sally Davies, Professor Dennis Dixon, Head of Bacteriology and Mycology at the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Health (NIH) in the USA and John Rex, Vice President and Head of Infection, Global Medicines Development.

Speaking at the conference, Dame Sally noted that the golden age of effective antibiotics has come to an end as no new class of drugs has been developed since 1987. She warned of the danger of going back to a pre-antibiotic era, where a simple infection could be a death sentence – a warning echoed by other speakers from around the globe.

During the debate, Neil Murray discussed how corporate R&D can be reinvigorated – outlining how Redx Pharma is building a new collaboration model in drug development.

Further background to the day can be found here:

www.scripintelligence.com/bioinfect2013/

Post-event follow up:

Watch the BioInfect 2013 highlights video



Dr Neil Murray speaking at BioInfect 2013



(left to right) John Stageman, Chairman Bionow; Dame Sally Davies, Chief Medical



Officer; John Rex, VP and Head of Infection, Global Medicines Development, AstraZeneca; Neil Murray, CEO, Redx Pharma